# Phase III Study of Coagulation FVIIa (Recombinant) in Congenital Hemophilia A or B Patients With Inhibitors

> **NCT02020369** · PHASE3 · COMPLETED · sponsor: **rEVO Biologics** · enrollment: 27 (actual)

## Conditions studied

- Hemophilia A With Inhibitors
- Hemophilia B With Inhibitors

## Interventions

- **BIOLOGICAL:** Coagulation Factor VIIa (Recombinant)

## Key facts

- **NCT ID:** NCT02020369
- **Lead sponsor:** rEVO Biologics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04
- **Primary completion:** 2015-07
- **Final completion:** 2015-08
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2017-06-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02020369

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02020369, "Phase III Study of Coagulation FVIIa (Recombinant) in Congenital Hemophilia A or B Patients With Inhibitors". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT02020369. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*